Note: One issue that isn’t really discussed in the health care bill is how devastating this bill is going to be for the elderly. It is likely that Medicaid funding would be drastically reduced. This may effect the elderly who have no family to take care of them or those who have little income saved up. I know that when my mother was very ill we could not afford to hire around the clock nursing care. Thankfully, Medicaid was available to help and she as able to get into a nursing home that provided excellent care. I don’t know what our family would have done without Medicaid. If this bill passes it’s going to have terrible consequences on the middle and lower income people in this country and not just for the elderly–almost everyone who doesn’t have a safety net is going to suffer. Alan
CBO and JCT estimate that enacting the Better Care Reconciliation Act of 2017 would reduce federal deficits by $321 billion over the coming decade and increase the number of people who are uninsured by 22 million in 2026 relative to current law.
An Amendment in the Nature of a Substitute [LYN17343] as Posted on the Website of the Senate Committee on the Budget on June 26, 2017
The Congressional Budget Office and the staff of the Joint Committee on Taxation (JCT) have completed an estimate of the direct spending and revenue effects of the Better Care Reconciliation Act of 2017, a Senate amendment in the nature of a substitute to H.R. 1628. CBO and JCT estimate that enacting this legislation would reduce the cumulative federal deficit over the 2017-2026 period by $321 billion. That amount is $202 billion more than the estimated net savings for the version of H.R. 1628 that was passed by the House of Representatives.
The Senate bill would increase the number of people who are uninsured by 22 million in 2026 relative to the number under current law, slightly fewer than the increase in the number of uninsured estimated for the House-passed legislation. By 2026, an estimated 49 million people would be uninsured, compared with 28 million who would lack insurance that year under current law.
Following the overview, this document provides details about the major provisions of this legislation, the estimated costs to the federal government, the basis for the estimate, and other related information, including a comparison with CBO’s estimate for the House-passed act.
A former clinical pharmacy manager from Jonesborough was sentenced to 16 months in federal prison Monday for healthcare fraud, which resulted in at least a $4.4 million loss to TennCare.
Upon 33-year-old Amber Reilly’s release from prison, she will be on probation for three years. Reilly pleaded guilty in October 2016 to one count of healthcare fraud. In her plea agreement, she admitted that between October 2014 and April 2016, she falsified prior authorizations, medical lab reports, and drug test results for at least 51 Hepatitis C patients who had prescriptions for expensive drugs used to treat Hepatitis C.
According to authorities, those patients had health insurance through TennCare, which does not pay for Hepatitis C prescriptions for patients who abuse illicit substances or who have limited or no scarring of the liver. The patients’ lab reports and drug tests showed they failed to meet TennCare eligibility requirements.
On May 4, 2017, the U.S. House of Representatives passed the American Health Care Act (AHCA), which would repeal major provisions of the Affordable Care Act (ACA). On June 22, 2017, the U.S. Senate released its own version of a repeal bill, the Better Care Reconciliation Act (BCRA), with a vote expected the following week. The Senate bill which would remove many of the Affordable Care Act’s monumental gains in insurance coverage and affordability.The Senate could vote as early as next week, even though it has not held a single public hearing. Neither the public nor many Senators have even seen the bill.
Like the AHCA, the Senate’s BCRA would end Medicaid expansion and change how the Medicaid program is funded, allowing states to opt to receive federal funds as either a block grant or under a per-capita cap. States would have the option to waive the ACA’s patient protections, including the essential health benefits (EHBS), eroding the protections for those with pre-existing conditions, including people with hepatitis B and hepatitis C. The legislation is likely to lead to higher premiums for low- and middle-income Americans. Any proposal to reduce Medicaid funding to states would only exacerbate the prevention and treatment barriers that patients currently face.
There will not be much time for debate or public input. Your Senators need to hear from you now. Ask your Senators to oppose the BCRA and any bill that reduces access to comprehensive coverage for many, particularly patients with liver disease, and will leave millions of Americans uninsured. It is imperative that all members of the Senate hear from their constituents, but the following Senators have expressed reservations about the bill and need to hear from you today:
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Vosevi®, an investigational, once-daily, single tablet regimen of sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients. The data included in the application support the use of SOF/VEL/VOX in patients with and without compensated cirrhosis, with all genotypes (GT1-6) of HCV infection regardless of prior therapy, including 8 weeks of treatment for HCV direct-acting antiviral (DAA)-naïve patients without cirrhosis, as well as 12 weeks of treatment for patients who have previously failed therapy with a DAA-containing regimen.
The CHMP positive opinion was adopted following an accelerated assessment procedure, reserved for medicinal products expected to be of major public health interest. The recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union, Norway and Iceland.
The MAA for SOF/VEL/VOX is supported by data from four Phase 3 studies. Two studies (POLARIS-1 and POLARIS-4), evaluated 12 weeks of the single tablet regimen in patients with genotypes 1-6 HCV infection previously treated unsuccessfully with DAA-containing regimens, including NS5A inhibitors. Two other studies (POLARIS-2 and POLARIS-3) evaluated 8 weeks of SOF/VEL/VOX in DAA-naïve patients with genotypes 1-6 HCV infection. Across POLARIS-1 and POLARIS-4, 97 percent of patients treated with SOF/VEL/VOX (n=431/445) achieved the primary efficacy endpoint of SVR12. In POLARIS-2, 95 percent of patients with genotypes 1-6 HCV infection with and without cirrhosis treated with SOF/VEL/VOX (n=477/501) achieved the primary efficacy endpoint of SVR12. In POLARIS-3, 96 percent of patients with genotype 3 infection and cirrhosis treated with SOF/VEL/VOX (n=106/110) achieved the primary efficacy endpoint of SVR12. The most common adverse events among patients who received SOF/VEL/VOX in the POLARIS studies were headache, fatigue, diarrhea and nausea.
If approved, MAVIRET™ will provide a shorter, 8-week, pan-genotypic (GT1-6), once-daily treatment option for the majority of people living with chronic hepatitis C virus (HCV)
MAVIRET would also be an additional HCV treatment option for patients with specific treatment challenges, such as those with compensated cirrhosis, chronic kidney disease and genotype 3
Final European Commission decision expected Q3 2017
Glecaprevir is Enanta’s second protease inhibitor being developed through its collaboration with AbbVie and is one of the two new direct-acting antivirals (DAAs) in MAVIRET
WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted AbbVie a positive opinion recommending marketing authorization of MAVIRET™ (glecaprevir/pibrentasvir), an investigational, pan-genotypic treatment for adults with chronic hepatitis C virus (HCV) infection. If approved, MAVIRET will be a once-daily, ribavirin-free, 8-week treatment option for HCV patients across all genotypes (GT1-6) without cirrhosis and new to treatment, who comprise the majority of people living with HCV.1 The European Commission will now review the CHMP opinion and a final decision is expected in the next quarter. Glecaprevir is Enanta’s second protease inhibitor being developed through its collaboration with AbbVie and is one of the two new direct-acting antivirals (DAAs) combined in MAVIRET.